Identification of FDA-approved oncology drugs with selective potency in high-risk childhood ependymoma.

Children with ependymoma (EPN) are cured in less than 50% of cases, with little improvement in outcome over the last several decades. Chemotherapy has not impacted survival in EPN, due in part to a lack of preclinical models that has precluded comprehensive drug testing. We recently developed two hu...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Mol Cancer Ther
Main Authors: Donson, Andrew M., Amani, Vladimir, Warner, Elliot A., Griesinger, Andrea M., Witt, Davis A., Levy, Jean M. Mulcahy, Hoffman, Lindsey M., Hankinson, Todd C, Handler, Michael H., Vibhakar, Rajeev, Dorris, Kathleen, Foreman, Nicholas K.
Formato: Artigo
Idioma:Inglês
Publicado: 2018
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6125158/
https://ncbi.nlm.nih.gov/pubmed/29925527
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-1185
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares